QualifyHQ Logo

GeoDeal AB

Modern, antibiotic free treatment of vaginal infectionsFounded in 2015 in Lund, Sweden, Gedea Biotech is dedicated to developing safe and effective, antibiotic-free treatments for vaginal infections. Our lead product pHyph is an antibiotic free treatment for bacterial vaginosis that strengthens the healthy vaginal microbiome, supporting good vaginal health also in the long term. pHyph is approved for CE-mark has under EU MDR since 2025. The approval demonstrates the efficacy and safety of pHyph in treating bacterial vaginosis. We want to launch pHyph in partnership with pharmaceutical companies established in women’s health. pHyph is launch ready in Europe and in the US we want to enter a partnership for remaining clinical studies and launch. Gedea is privately held and backed by experienced life science investors. Its lead product pHyph represents a new standard of care in women’s health.

Founded

2015

Revenue

$1.0M - $2.5M

Funding

$7.3M

View similar companies

Qualify this Company in

minutes

While other tools waste time, we help you qualify better-fit companies in minutes, so your pipeline stays healthy, your team stays productive, and your deals move faster.

Start free trial

Start 7-Day Free Trial